Executive Summary of the Vulvodynia Therapeutic Research Summit

Jill M Krapf1, Paul J Yong, Marlene D Berke

  • 1Center for Vulvovaginal Disorders Florida, Tampa, Florida; the Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada; the Department of Psychology, Yale University, New Haven, Connecticut; the Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachussets; the Division of Obstetrics and Gynecology, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden; the Department of Obstetrics and Gynecology, Galilee Medical Center and Bar-Ilan University Faculty of Medicine, Nahariya, Israel; the Department of Pharmacology and Physiology and the Department of Obstetrics and Gynecology, University of Rochester, Rochester, the AIM Center for Personalized Medicine, Purchase, and the Centers for Vulvovaginal Disorders, New York, New York; San Diego Sexual Medicine, San Diego, California; the Department of Perioperative Medicine, Clinical Center/National Institutes of Health, Bethesda, Maryland; the Center for Pelvic Medicine and Drexel University College of Medicine, Philadelphia, Pennsylvania; Innovative Pain Care, Marietta, Georgia; and the Department of Obstetrics and Gynecology, George Washinton University, Washington, DC.

Obstetrics and Gynecology
|November 6, 2025
PubMed